Novo Nordisk and Eli Lilly are currently a duopoly in the obesity market, which reached a value of $24 billion last year ...

In a new white paper from the World Without Disease initiative, a 2024 update is provided of the current endeavours and ...

Biogen says it is the first drugmaker in the US to get FDA approval for a biosimilar of Roche’s $3 billion blockbuster product Actemra. The intravenous biosimilar of IL-6 inhibitor Actemra ...

Novartis has said it will shut down two MorphoSys sites in Germany and the US, with the loss of around 330 jobs, after ...

Vertex Pharma's non-opioid painkiller suzetrigine was unable to perform better than placebo in a phase 2 trial in lumbar ...

Novo Holdings' $16.5 billion acquisition of US contract development and manufacturing organisation (CDMO) Catalent has been ...

While Neuralink has been grabbing headlines due to its association with controversial billionaire Musk, other companies - ...

An experimental therapy for Parkinson's disease being developed by Roche and Prothena has missed the mark in a phase 2b trial ...

Anglo-US biotech Ottimo Pharma has completed a big early-stage biotech financing, raising $140 million for its PD-1 and VEGF ...

The 2022 Inflation Reduction Act (IRA) has introduced significant challenges for the pharmaceutical industry, altering the ...

The big pharma is paying Hansoh $112 million upfront to place its bet on oral GLP-1 receptor agonist HS-1035, with another $1 ...

Mesoblast ran an additional clinical trial to support its latest application which revealed that in 54 paediatric patients with severe, acute GvHD, Ryoncil treatment achieved a complete response in 16 ...